1
|
Kander EM, Shah MH, Zhou Y, Goyal A, Palmer JD, Owen DH, Shilo K, Patel G, Raval RR, Gonzalez J, Nguyen M, Olek E, Kherani J, Rothenberg SM, Konda B. Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid. Clin Lung Cancer 2020; 22:e442-e445. [PMID: 32660930 DOI: 10.1016/j.cllc.2020.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2020] [Revised: 06/02/2020] [Accepted: 06/11/2020] [Indexed: 10/24/2022]
Affiliation(s)
- Elizabeth M Kander
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Manisha H Shah
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Ye Zhou
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Ashima Goyal
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Joshua D Palmer
- Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Dwight H Owen
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Konstantin Shilo
- Division of Surgical Pathology, Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Gopal Patel
- Division of Surgical Pathology, Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Raju R Raval
- Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Javier Gonzalez
- Division of Neuro-Oncology, Department of Neurology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Michele Nguyen
- Loxo Oncology, Inc, a whole owned subsidiary of Eli Lilly & Co, Stamford, CT
| | - Elizabeth Olek
- Loxo Oncology, Inc, a whole owned subsidiary of Eli Lilly & Co, Stamford, CT
| | - Jennifer Kherani
- Loxo Oncology, Inc, a whole owned subsidiary of Eli Lilly & Co, Stamford, CT
| | | | - Bhavana Konda
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
| |
Collapse
|
2
|
Kander EM, Zhao Q, Bhat SA, Hirsch J, Byrd JC, Ooka L, Wiczer T, Woyach JA, Awan FT, Rogers KA, Wang TF. Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. Br J Haematol 2019; 187:399-402. [PMID: 31531846 DOI: 10.1111/bjh.16209] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Accepted: 07/31/2019] [Indexed: 01/08/2023]
Affiliation(s)
| | - Qiuhong Zhao
- Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Seema A Bhat
- Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Jessica Hirsch
- Department of Pharmacy, Spectrum Health, Grand Rapids, MI, USA
| | - John C Byrd
- Division of Hematology, The Ohio State University, Columbus, OH, USA.,Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA
| | - Lauren Ooka
- Department of Pharmacy, Franciscan Health Indianapolis, Indianapolis, IN, USA
| | - Tracy Wiczer
- Department of Pharmacy, The Ohio State University, Columbus, OH, USA
| | - Jennifer A Woyach
- Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Farrukh T Awan
- Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Kerry A Rogers
- Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Tzu-Fei Wang
- Division of Hematology, The Ohio State University, Columbus, OH, USA
| |
Collapse
|
3
|
Kander EM, Moliterno AR, Rademaker A, Streiff MB, Spivak JL, Stein BL. Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era. J Natl Compr Canc Netw 2017; 14:1238-1245. [PMID: 27697978 DOI: 10.6004/jnccn.2016.0133] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2016] [Accepted: 06/02/2016] [Indexed: 11/17/2022]
Abstract
Polycythemia vera (PV) is an acquired clonal hematopoietic stem cell disorder characterized by an overproduction of red blood cells, white blood cells, and platelets; thrombotic and hemorrhagic complications; and an increased risk of transformation to myelofibrosis and acute leukemia. In 1967, the Polycythemia Vera Study Group proposed the optimal approach to diagnosis and treatment of PV, and in 2002, investigators from Johns Hopkins University School of Medicine surveyed the practice patterns of hematologists as they pertained to PV. Since this survey, the JAK2 V617F mutation was discovered, leading to a new era of discovery in the disease pathogenesis, diagnosis, and classification and treatment of PV. Our objective was to survey hematologists in the diagnosis and treatment of PV in the modern, post-JAK2 V617F discovery era. An anonymous 17-question survey was emailed to members of the Myeloproliferative Neoplasm (MPN) Research Foundation database and Aplastic Anemia and MDS International Foundation. A total of 71 surveys were used in the analysis. Diagnostic testing varied according to the respondent's clinical experience and practice type. In addition, there were marked differences in target hematocrit and platelet count among those surveyed. There continue to be variations in diagnosis and treatment of PV despite WHO guidelines and the JAK2 discovery. US-based guidelines for MPNs are needed to create consistency in the management of PV and other MPNs.
Collapse
Affiliation(s)
- Elizabeth M Kander
- From the Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; and Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Alison R Moliterno
- From the Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; and Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Alfred Rademaker
- From the Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; and Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Michael B Streiff
- From the Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; and Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Jerry L Spivak
- From the Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; and Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Brady L Stein
- From the Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; and Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
4
|
Hyatt JPK, McCall GE, Kander EM, Zhong H, Roy RR, Huey KA. PAX3/7 expression coincides with MyoD during chronic skeletal muscle overload. Muscle Nerve 2008; 38:861-6. [PMID: 18508329 DOI: 10.1002/mus.21006] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Paired box (Pax) proteins 3 and 7 are key determinants for embryonic skeletal muscle development by initiating myogenic regulatory factor (MRF) gene expression. We show that Pax3 and 7 participate in adult skeletal muscle plasticity during the initial responses to chronic overload (< or =7 days) and appear to coordinate MyoD expression, a member of the MRF family of genes. Pax3 and 7 mRNA were higher than control within 12 h after initiation of overload, preceded the increase in MyoD mRNA on day 1, and peaked on day 2. On days 3 and 7, Pax7 mRNA remained higher than control, suggesting that satellite cell self-renewal was occurring. Pax3 and 7 and MyoD protein levels were higher than control on days 2 and 3. These data indicate that Pax3 and 7 coordinate the recapitulation of developmental-like regulatory mechanisms in response to growth-inducing stimuli in adult skeletal muscle, presumably through activation of satellite cells.
Collapse
Affiliation(s)
- Jon-Philippe K Hyatt
- Department of Human Science, School of Nursing and Health Studies, Georgetown University, 3700 Reservoir Rd., Washington, DC 20057, USA.
| | | | | | | | | | | |
Collapse
|
5
|
Kander EM, McCall GE, Zhong H, Roy RR, Hyatt JK. Early time course of Pax3, Pax7, and MyoD protein content in the functionally overloaded rat plantaris muscle. FASEB J 2007. [DOI: 10.1096/fasebj.21.6.a945-a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Gary E. McCall
- University of Puget Sound1500 North Warner St.TacomaWA98416
| | - Hui Zhong
- UCLA1320 Gonda BldgLos AngelesCA90095
| | | | | |
Collapse
|